ArticleRevista da Associacao Medica Brasileira (1992)2026
Retrospective study of inflammatory markers in high-grade cervical lesions.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the predictive value of systemic inflammation markers for abnormal cervical screening results and high-grade cervical lesions in women participating in a human papillomavirus- and cytology-based screening program, thereby determining colposcopy indications more accurately to reduce unnecessary colposcopy requests and prevent overtreatment.
methodsA total of 2,758 women who underwent cervical cancer screening between 2020 and 2025 were included in this retrospective cross-sectional study. Abnormal screening results were defined as abnormal cytology (≥Atypical squamous cells of undetermined significance [ASC-US]) and/or high-risk human papillomavirus positivity. Hematological parameters measured within 1 month prior to screening were used to calculate neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index. Continuous variables were evaluated using nonparametric tests, and the independent predictors of abnormal screening results and high-grade lesions were identified using logistic regression models.
resultsNeutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index values were significantly higher in the abnormal smear groups and in human papillomavirus -positive patients (all p<0.001). Neutrophil-to-lymphocyte ratio displayed the highest diagnostic performance for high-grade lesions (area under the curve=0.871; cutoff value >4.41, sensitivity 66.7%, specificity 99.2%), followed by systemic immune-inflammation index (area under the curve=0.847), while platelet-to-lymphocyte ratio showed lower specificity (area under the curve=0.741).
conclusionIn conclusion, our findings suggest that inflammatory markers are associated with abnormal cervical screening results. To determine the significance and clinical utility of serum inflammatory markers, multicenter clinical trials involving larger patient cohorts are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.